CEO Yvonne Greenstreet said Q1 “demonstrated continued strength of the business,” highlighting “over $900 million in total net revenues from AMVUTTRA and ONPATTRO combined” and “more than $1 billion ...
Coramitug is designed to clear toxic protein deposits from the heart, offering a new approach to treating ATTR cardiomyopathy ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2026, and reviewed recent ...
Reiterated full-year 2026 TTR product sales guidance of $4.4 billion to $4.7 billion, assuming significantly higher ...
TTR Sotheby’s International Realty, the firm that sells luxury real estate to the rich and famous in the Washington, D.C., metropolitan region, started off the last month of the year with leadership ...
The presence of genetic variants that affect the stabilization of the tetrameric protein transthyretin (TTR) is associated with both all-cause and cardiovascular mortality, according to new data from ...
Spontaneous ruptures of the distal biceps tendon may be a marker of wild-type transthyretin (TTR) cardiac amyloidosis, a single-center study found, potentially giving physicians an easy way to ...
This transcript has been edited for clarity. Gayatri Acharya, MD: Greetings. I'm Dr Gayatri Acharya, cardiology fellow at Mayo Clinic. During today's roundtable, we'll be discussing cardiac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results